Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant of COVID-19

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today confirmed that Omicron variant B.1.1.529, designated by the World Health Organization as a Variant of Concern, does not impact the capability of the Fluidigm® Advanta™ Dx SARS-CoV-2 RT-PCR Assay to detect the virus that causes COVID-19, based on in silico analyses of the most current databases.